Theodore F. Logan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Theodore F. Logan has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Asim Amin
Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, Charlotte, NC, 28204, USA.
2 shared publications - David F. McDermott
Harvard Medical School, Boston, Massachusetts
2 shared publications - Joseph I. Clark
Division of Hematology-Oncology, Loyola University Medical Center, Maywood, IL
2 shared publications - Anita Giobbie-Hurder
Dana-Farber Cancer Institute, Boston, MA
1 shared publication - Arkadiusz Z. Dudek
Division of Hematology/Oncology, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
1 shared publication - Brendan D. Curti
Providence Cancer Institute, Franz Clinic, Portland, OR
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of Immunotherapy
The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients With Metastatic Melanoma
High-dose aldesleukin (HD-IL2) produces durable responses in a portion of patients with melanoma. In the modern era, HD-IL2 is a key component of tumor infiltrating lymphocyte (TIL) therapy and newer forms of IL-2 have shown promise across tumor types. The Select trial aimed to validate biomarkers of HD-IL2 responsiveness. First, we retrospectively identified a proinflammatory (Class 2) gene expression profile (GEP) associated with HD-IL2 responsiveness. Prospective biomarker discovery was then performed in patients with metastatic melanoma receiving HD-IL2 with a primary objective to validate Class 2 GEP as a predictor of efficacy. Additional analyses examined potential serum and tissue protein biomarkers. Retrospective GEP data (n=28) demonstrated a response benefit in GEP Class 2 versus Class 1 subgroup (ORR: 86% vs. 38%; P =0.0384). In the prospective cohort with GEP data (n=152), HD-IL2 resulted in an ORR of 17.7%, a median PFS of 2.4 months (95% CI: 2.1–2.8 mo) and median OS of 21.2 months (95% CI: 19.0–25.5 mo). Using gene set enrichment analysis, Class 2 GEP tumors had a higher response (21% vs. 12%; P =0.2678) and 2-year OS (37.2% vs. 22.4% P =0.1229) in comparison to Class 1 but did not meet predefined levels of significance. Serum proteomic analysis highlighted that low C-reactive protein was associated with response. In conclusion, although Class 2 GEP did not meet the predefined measure of significance, it correlated with response and lower CRP levels were associated with improved outcomes. Building on this work, future biomarker studies are primed to guide contemporary IL-2 administration
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of Immunotherapy
Open AccessThe High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients With Metastatic Melanoma
High-dose aldesleukin (HD-IL2) produces durable responses in a portion of patients with melanoma. In the modern era, HD-IL2 is a key component of tumor infiltrating lymphocyte (TIL) therapy and newer forms of IL-2 have shown promise across tumor types. The Select trial aimed to validate biomarkers of HD-IL2 responsiveness. First, we retrospectively identified a proinflammatory (Class 2) gene expression profile (GEP) associated with HD-IL2 responsiveness. Prospective biomarker discovery was then performed in patients with metastatic melanoma receiving HD-IL2 with a primary objective to validate Class 2 GEP as a predictor of efficacy. Additional analyses examined potential serum and tissue protein biomarkers. Retrospective GEP data (n=28) demonstrated a response benefit in GEP Class 2 versus Class 1 subgroup (ORR: 86% vs. 38%; P =0.0384). In the prospective cohort with GEP data (n=152), HD-IL2 resulted in an ORR of 17.7%, a median PFS of 2.4 months (95% CI: 2.1–2.8 mo) and median OS of 21.2 months (95% CI: 19.0–25.5 mo). Using gene set enrichment analysis, Class 2 GEP tumors had a higher response (21% vs. 12%; P =0.2678) and 2-year OS (37.2% vs. 22.4% P =0.1229) in comparison to Class 1 but did not meet predefined levels of significance. Serum proteomic analysis highlighted that low C-reactive protein was associated with response. In conclusion, although Class 2 GEP did not meet the predefined measure of significance, it correlated with response and lower CRP levels were associated with improved outcomes. Building on this work, future biomarker studies are primed to guide contemporary IL-2 administration
- Open Access
- 19 December 2017
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1) , 102
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Background Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therapy (IL-2) documented in the PROCLAIMSM registry data base from 2008 to 2016 (NCT01415167, August 9, 2011). Methods Reports on 1535 patients, including 623 with metastatic melanoma (mM) and 919 with metastatic renal cell cancer (mRCC) (7 patients had both diseases), were queried for irAEs. The timing of the event was categorized as occurring before, during or after IL-2 or related to any checkpoint inhibitor (CPI). mM patients and mRCC patients were analyzed separately. Tumor control [complete + partial response + stable disease (CR + PR + SD) was compared between those experiencing no irAE versus those with the development of irAEs. Survival was analyzed by tumor type related to timing of irAE and IL-2, and in those with or without exposure to CPI. Results Median follow-up was 3.5+ years (range 1–8+ years), 152 irAEs were reported in 130 patients (8.4% of all PROCLAIMSM patients): 99 (16%) in mM and 53 (5.8%) in mRCC patients. 31 irAEs occurred prior to IL-2, 24 during IL-2, and 97 after IL-2 therapy. 74 irAEs were attributed to IL-2 only (during/ after IL-2). Of the 97 post IL-2 irAEs, 24 were attributed to CPI, and 15 could not be distinguished as caused by IL-2 or CPI. Tumor control was 71% for those experiencing irAE, and 56% for those with no irAE (p = 0.0008). Overall survival was significantly greater for those experiencing irAEs during/ after IL-2 therapy, compared to those with no irAE or irAE before IL-2 therapy, in mM patients, median 48 months vs 18 months (p < 0.0001), and in mRCC patients, median 60 months vs 40 months (p = 0.0302), independent of CPI-related irAEs. IL-2-related irAEs were primarily vitiligo and thyroid dysfunction (70% of IL-2 related irAEs), with limited further impact. Conclusions irAEs following IL-2 therapy are associated with improved tumor control and overall survival. IrAEs resulting from IL-2 and from CPIs are qualitatively different, and likely reflect different mechanisms of action of immune activation and response.
- 19 December 2017
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1) , 102
Open AccessImproved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Background Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therapy (IL-2) documented in the PROCLAIMSM registry data base from 2008 to 2016 (NCT01415167, August 9, 2011). Methods Reports on 1535 patients, including 623 with metastatic melanoma (mM) and 919 with metastatic renal cell cancer (mRCC) (7 patients had both diseases), were queried for irAEs. The timing of the event was categorized as occurring before, during or after IL-2 or related to any checkpoint inhibitor (CPI). mM patients and mRCC patients were analyzed separately. Tumor control [complete + partial response + stable disease (CR + PR + SD) was compared between those experiencing no irAE versus those with the development of irAEs. Survival was analyzed by tumor type related to timing of irAE and IL-2, and in those with or without exposure to CPI. Results Median follow-up was 3.5+ years (range 1–8+ years), 152 irAEs were reported in 130 patients (8.4% of all PROCLAIMSM patients): 99 (16%) in mM and 53 (5.8%) in mRCC patients. 31 irAEs occurred prior to IL-2, 24 during IL-2, and 97 after IL-2 therapy. 74 irAEs were attributed to IL-2 only (during/ after IL-2). Of the 97 post IL-2 irAEs, 24 were attributed to CPI, and 15 could not be distinguished as caused by IL-2 or CPI. Tumor control was 71% for those experiencing irAE, and 56% for those with no irAE (p = 0.0008). Overall survival was significantly greater for those experiencing irAEs during/ after IL-2 therapy, compared to those with no irAE or irAE before IL-2 therapy, in mM patients, median 48 months vs 18 months (p < 0.0001), and in mRCC patients, median 60 months vs 40 months (p = 0.0302), independent of CPI-related irAEs. IL-2-related irAEs were primarily vitiligo and thyroid dysfunction (70% of IL-2 related irAEs), with limited further impact. Conclusions irAEs following IL-2 therapy are associated with improved tumor control and overall survival. IrAEs resulting from IL-2 and from CPIs are qualitatively different, and likely reflect different mechanisms of action of immune activation and response.
- Open Access
- 21 April 2015
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 14
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Background AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Methods Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Results Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. Conclusions AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. Clinical Trial Registry #NCT00678119
- 21 April 2015
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 14
Open AccessSurvival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Background AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Methods Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Results Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. Conclusions AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. Clinical Trial Registry #NCT00678119